Oric Pharmaceuticals
Ali Reza Mohebbi is a seasoned professional in the field of chemistry and materials science, currently serving as a Senior Manager in CMC at ORIC Pharmaceuticals Inc. since June 2022, while also holding the position of Senior Research Scientist I at AMRI since August 2018. Ali Reza has a robust background in teaching as an Adjunct Faculty at Northeastern Illinois University and has contributed significantly to research in organic materials and electronic applications through roles at Polyera Corporation, UW-Madison, and the University of California, Santa Barbara. Ali Reza holds a PhD in Organic Chemistry and NanoChemistry from the University of Kiel, Germany, and has an extensive academic foundation, including earlier degrees in chemistry from the University of Isfahan and the Chemistry & Chemical Engineering Research Center of Iran.
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.